Background And Aims: Colonoscopy is less protective for cancers of the right side of the colon than for distal colon cancers. Repeat examination of the right side of the colon has been suggested to increase adenoma detection and potentially provide greater protection against the development of cancers of the right side of the colon. Our prospective study assessed the yield of a second forward-view examination of the right side of the colon done immediately after the initial examination.
Methods: All men 50 to 75 years of age undergoing screening or surveillance colonoscopy at the West Haven Veterans Affairs Medical Center were invited to participate. A second forward-view examination was performed if the Boston Bowel Preparation Scale score was 8 to 9 (scale = 0-9) with right a side of the colon segment score of 2 to 3 (scale = 0-3). The primary outcome was the per-patient adenoma detection rate (including sessile serrated polyps) on a repeated examination of the right side of the colon, defined as the number of patients with ≥1 adenoma on the second examination of the right side of the colon divided by total number of patients. An increase in the adenoma detection rate (ADR) was a secondary outcome.
Results: Repeated examination of the right side of the colon, performed in 280 patients, revealed additional adenomas in 43 patients (15.4%; 95% confidence interval [CI] of difference, 11.3%-21.0%). The overall ADR increased by 3.2% (95% CI, 1.1%-5.3%) after the second examination of the right side of the colon; the ADR for the right side of the colon increased by 6.7% (95% CI, 3.8%-9.7%). Ten patients (3.6%) had a change in their screening/surveillance interval with the addition of findings on the second examination of the right side of the colon.
Conclusion: A substantial 15.4% of patients had additional adenomas detected on a second forward-view examination of the right side of the colon, whereas the overall ADR increased significantly by 3.2%. Given the lack of additional training or equipment required, repeated forward-view examination of the right side of the colon is a simple, readily available method to achieve a modest improvement in the ADR.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912931 | PMC |
http://dx.doi.org/10.1016/j.gie.2015.12.030 | DOI Listing |
J Immunother Cancer
December 2024
Department of Clinical Laboratory, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China
Objective: Targeting CD47 for cancer immunotherapy has been studied in many clinical trials for the treatment of patients with advanced tumors. However, this therapeutic approach is often hampered by on-target side effects, physical barriers, and immunosuppressive tumor microenvironment (TME).
Methods: To improve therapeutic efficacy while minimizing toxicities, we engineered an oncolytic vaccinia virus (OVV) encoding an anti-CD47 nanobody (OVV-αCD47nb).
Sci Rep
January 2025
School of Basic Medicine, Qingdao Medical College, Qingdao University, Qingdao, China.
Tofacitinib (Tof), a commercially available pan-Janus kinases inhibitor, is approved for the treatment of moderate to severe ulcerative colitis. However, its clinical application is limited due to dose-dependent systemic side effects. The present study aims to develop an efficient oral colon-targeted drug delivery systems using prebiotic pectin (Pcn) and chitosan (Csn) polysaccharides as a shell, with Tof loaded into a Bovine Serum Albumin (BSA) core, and improving it with chondroitin sulfate (Chs), thus constructing Tof@BSA-Chs-CP nanoparticles (NPs).
View Article and Find Full Text PDFBioorg Med Chem Lett
January 2025
Department of Chemistry, Simon Fraser University Burnaby British Columbia Canada. Electronic address:
Prostaglandin E receptor type 4 (EP4) agonists have been shown to be effective in treating experimental ulcerative colitis (UC) in animals and in human clinical trials, but their development has been impeded by unacceptable systemic side effects. In this study, a series of methylene phosphate prodrugs of a highly potent and selective prostaglandin EP4 receptor agonist were designed to target and remain localized in the gastrointestinal (GI) tract after either oral or rectal instillation. The prodrugs were designed to be converted to liberate active EP4 agonist by intestinal alkaline phosphate (IAP), a ubiquitous enzyme found at the luminal of the intestinal wall thus exposing the colon epithelial barrier while reducing systemic exposure to the active agonist.
View Article and Find Full Text PDFMicrobiol Spectr
January 2025
Laboratory of Microbiology and Immunology, School of Basic Medical Science, Inner Mongolia Medical University, Hohhot, China.
Colorectal cancer (CRC) is one of the malignant tumors globally, with high morbidity and mortality rates. The mainstay treatment of CRC includes surgery, radiotherapy, and chemotherapy. However, these treatments are associated with a high recurrence rate, poor prognosis, and highly toxic side effects.
View Article and Find Full Text PDFNeurogastroenterol Motil
January 2025
Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Introduction: Colonic manometry (CM) is a diagnostic procedure used to evaluate pediatric patients with refractory constipation, fecal incontinence, Hirschsprung disease, and pediatric intestinal pseudo-obstruction. Pan-colonic high-amplitude propagated contractions (HAPCs), measured by CM, reflect an intact neuromuscular function of the colon. Current guidelines recommend starting CM with fasting recording for 1-2 h, but no prior evaluation has determined the diagnostic yield of the fasting phase.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!